BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and ...

"The financing agreement provides TransCode with financial flexibility and ensures that TransCode can maintain operational momentum as we conduct our Phase 2a trial for our lead clinical program, ...

Spoiler alert! We're discussing important plot points and the ending of “Ready or Not 2: Here I Come” (in theaters now), so beware if you haven’t seen it yet. Samara Weaving’s “Ready or Not” character ...

Facing life behind bars or the death penalty under the “special circumstances” charges, Nick Reiner‘s public defender Kimberly Green entered the plea this morning before Los Angeles County Superior ...

The claim was made in a habeas corpus petition filed by Maxwell in December Sylvain Gaboury/Patrick McMullan via Getty Ghislaine Maxwell claimed in a habeas corpus petition that four co-conspirators ...

Contributing Editor Jan Ozer recently spoke with Alex Davies, senior analyst at Rethink Technology Research, about Rethink’s new report, “The Media and Entertainment Transcoding Workload and Device ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

Although software transcoding is accept­able for transcoding most VOD streams and even low-volume live programming, most high-volume live applications need hardware for efficient transcoding, both to ...

TransCode Therapeutics (NASDAQ:RNAZ) announces to raise $10M through the purchase and sale of 10.25M shares of its common stock and warrants to purchase up to 10.25M shares of common stock priced ...

Microsoft PowerToys is a free application that brings a bunch of advanced features to Windows for power users. Some of those tools give you more control over your mouse and keyboard settings. Others ...

TransCode Therapeutics Inc. (NASDAQ:RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead ...